Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 9, 2010, Pages 741-748

  Rombach, S M ^a   Dekker, N ^a   Bouwman, M G ^a   Linthorst, G E ^a   Zwinderman, A H ^a   Wijburg, F A ^a   Kuiper, S ^a   vd Bergh Weerman, M A ^a   Groener, J E M ^a   Poorthuis, B J ^a   Hollak, C E M ^a   Aerts, J M F G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Fabry disease; Lysoglycolipids; Pathogenesis

Indexed keywords

ALPHA GALACTOSIDASE; GLOBOTRIAOSYLSPHINGOSINE; SPHINGOSINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); DISEASE SEVERITY; FABRY DISEASE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; WHITE MATTER;

EID: 77954959657     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.05.003     Document Type: Article

References (37)

1. Brady R.O., Gal A.E., Bradley R.M., Martensson E. WALL, Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J. Med. 1967, 276:1163-1167.
2. Sweeley C.C., Klionsky B. Fabry's disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. J. Biol. Chem. 1963, 238:3148-3150.
3. Desnick R.J., Ioannou Y.A., Eng C.M. alpha-Galactosidase A deficiency: Fabry disease. The metabolic and molecular bases of inherited disease 2001, vol 3:3733-3774. 8 ed. A.L. Beaudet, C.R. BeaudetScriver, D. Valle, W.S. Sly (Eds.).
4. Schiffmann R. Fabry disease. Pharmacol. Ther. 2009, 122(1):65-77.
5. MacDermot K.D., Holmes A., Miners A.H. Natural history of Fabry disease in affected males and obligate carrier females. J. Inherit. Metab. Dis. 2001, 24(Suppl 2):13-14.
6. Vonscheidt S.W., Eng C.M., Fitzmaurice T.F., Erdmann E., Hubner G., Olsen E.G., et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J. Med. 1991, 324(6):395-399.
7. Nakao S., Takenaka T., Maeda M., Kodama C., Tanaka A., Tahara M., et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J. Med. 1995, 333(5):288-293.
8. Whybra C., Kampmann C., Willers I., Davies J., Winchester B., Kriegsmann J., et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J. Inherit. Metab. Dis. 2001, 24(7):715-724.
9. Gupta S., Ries M., Kotsopoulos S., Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore). 2005, 84(5):261-268.
10. Deegan P.B., Baehner A.F., Barba Romero M.A., Hughes D.A., Kampmann C., Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. J. Med. Genet. 2006, 43(4):347-352.
11. Wang R.Y., Lelis A., Mirocha J., Wilcox W.R. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet. Med. 2007, 9(1):34-45.
12. Vedder A.C., Linthorst G.E., van Breemen M.J., Groener J.E., Bemelman F.J., Strijland A., et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J. Inherit. Metab. Dis. 2007, 30(1):68-78.
13. Linthorst G.E., Poorthuis B.J., Hollak C.E. Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results. J. Am. Coll. Cardiol. 2008, 51(21):2082-2083.
14. Popli S., Leehey D.J., Molnar Z.V., Nawab Z.M., Ing T.S. Demonstration of Fabry's disease deposits in placenta. Am. J. Obstet. Gynecol. 1990, 162(2):464-465.
15. Vedder A.C., Strijland A., vd Bergh Weerman M.A., Florquin S., Aerts J.M., Hollak C.E. Manifestations of Fabry disease in placental tissue. J. Inherit. Metab. Dis. 2006, 29(1):106-111.
16. Young E., Mills K., Morris P., Vellodi A., Lee P., Waldek S., et al. Is globotriaosylceramide a useful biomarker in Fabry disease?. Acta Paediatr. Suppl. 2005, 94(447):51-54.
17. Bekri S., Lidove O., Jaussaud R., Knebelmann B., Barbey F. The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature. Cardiovasc. Hematol. Agents Med. Chem. 2006, 4(4):289-297.
18. Whitfield P.D., Calvin J., Hogg S., O'Driscoll E., Halsall D., Burling K., et al. Monitoring enzyme replacement therapy in Fabry disease-role of urine globotriaosylceramide. J. Inherit. Metab. Dis. 2005, 28(1):21-33.
19. Auray-Blais C., Cyr D., Mills K., Giguere R., Drouin R. Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease. J. Inherit. Metab. Dis. 2007, 30(1):106.
20. Aerts J.M., Groener J.E., Kuiper S., Donker-Koopman W.E., Strijland A., Ottenhoff R., et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(8):2812-2817.
21. Kalliokoski R.J., Kalliokoski K.K., Penttinen M., Kantola I., Leino A., Viikari J.S., et al. Structural and functional changes in peripheral vasculature of Fabry patients. J. Inherit. Metab. Dis. 2006, 29(5):660-666.
22. Barbey F., Brakch N., Linhart A., Jeanrenaud X., Palecek T., Bultas J., et al. Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease. Acta Paediatr. Suppl. 2006, 95(451):63-68.
23. Boutouyrie P., Laurent S., Laloux B., Lidove O., Grunfeld J.P., Germain D.P. Arterial remodelling in Fabry disease. Acta Paediatr. Suppl. 2002, 91(439):62-66.
24. Blom D., Speijer D., Linthorst G.E., Donker-Koopman W.G., Strijland A., Aerts J.M. Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA. Am. J. Hum. Genet. 2003, 72(1):23-31.
25. Levey A.S., Coresh J., Greene T., Stevens L.A., Zhang Y.L., Hendriksen S., et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 2006, 145(4):247-254.
26. Schwartz G.J., Munoz A., Schneider M.F., Mak R.H., Kaskel F., Warady B.A., et al. New equations to estimate GFR in children with CKD. J. Am. Soc. Nephrol. 2009, 20(3):629-637.
27. Levy D., Savage D.D., Garrison R.J., Anderson K.M., Kannel W.B., Castelli W.P. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am. J. Cardiol. 1987, 59(9):956-960.
28. Germain D.P., Avan P., Chassaing A., Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med. Genet. 2002, 3:10.
29. Whybra C., Kampmann C., Krummenauer F., Ries M., Mengel E., Miebach E., et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin. Genet. 2004, 65(4):299-307.
30. Groener J.E., Poorthuis B.J., Kuiper S., Helmond M.T., Hollak C.E., Aerts J.M. HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma. Clin. Chem. 2007, 53(4):742-747.
31. D. Levy, P.W. Wilson, K.M. Anderson, W.P. Castelli, Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study. Am. Heart J. 119 (3 Pt 2) 71 (1990) 2-7.
32. Mitsias P., Levine S.R. Cerebrovascular complications of Fabry's disease. Ann. Neurol. 1996, 40(1):8-17.
33. Brakch N., Dormond O., Bekri S., Golshayan D., Correvon M., Mazzolai L., et al. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur. Heart J. 2010, 31(1):67-76.
34. Michel M.C., Mulders A.C., Jongsma M., Alewijnse A.E., Peters S.L. Vascular effects of sphingolipids. Acta Paediatr. Suppl. 2007, 96(455):44-48.
35. Schiffmann R., Kopp J.B., Austin H.A., Sabnis S., Moore D.F., Weibel T., et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001, 285(21):2743-2749.
36. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J. Med. 2001, 345(1):9-16.
37. Vedder A.C., Linthorst G.E., Houge G., Groener J.E., Ormel E.E., Bouma B.J., et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2mg/kg. PLoS ONE 2007, 2(7):e598.